TOP 100 MEDICAL SITES
| |||
|
| |||
| |||
|
| |||
| Why Would an Insider Be Selling Protalix Shares Now of All Times? Shlomi Cohen submits: Among the shares in Israeli companies in my portfolio tracked by "Globes", Protalix Biotherapeutics Inc. (AMEX:PLX) can be expected to attract the most attention over the coming weeks. It is a rare situation in our area - a biotech company that grew from an Office of the Chief Scientist incubator to reach a market cap of $500 million, on the verge of completing a clinical trial for a drug aimed at a market of over $1 billion in annual sales. In the next few days, the last patient will complete the administration of the Gaucher disease drug, and the company said that in October it will report the results. At the same time, the company is handing the US Food and Drug Administration (FDA), in stages, the application of authorization of the drug, since it gained FDA fast track designation.Complete Story » seekingalpha.com |
The Latest on Cytori Mike Havrilla submits:The stock research section of BioMedReports.com has been updated to reflect the most recent corporate presentation for Cytori Therapeutics (NASDAQ:CYTX), following the company’s presentation at the Rodman & Renshaw Healthcare conference last week. Click here to visit Cytori’s corporate profile page at OneMedPlace, which also includes a video interview with CEO Christopher Calhoun. A special thanks to Cytori’s Director of IR and Media Relations, Tom Baker, for sending me the latest corporate presentation and speaking with me today for this article so that I am able to provide some color and clarity beyond the recent news headlines and developments for the company. Complete Story » seekingalpha.com |
Medicare Cuts Play Into Larger Debate Senators battled over legislation to forestall a cut in Medicare payments to doctors, trying to seize the advantage in the larger health debate. online.wsj.com |
Alliance HealthCare Services Announces Proposed Private Offering of $200 Million of Senior Notes (Business Wire) NEWPORT BEACH, Calif.----Alliance HealthCare Services, Inc. announced today that it intends to offer, subject to market and other conditions, $200 million aggregate principal amount of seven-year senior notes in a private offering. us.rd.yahoo.com |
China Biotech Week in Review: Year-End IPOs ChinaBio Today submits: At the beginning of 2009, IPO activity was at a standstill. But as the year progressed, and the threat of a complete financial disaster receded, a few companies managed to complete transactions that made them publicly owned entities, including several representatives of the China life science sector. We looked at how they fared, noticing a huge difference between those that listed in China and those who chose a US exchange for their home.In mid-summer of 2009, China lifted its IPO ban, allowing companies once again to access public markets (see story). The first entry, a successful transaction, was Guilin Sanjin Pharmaceutical Co. (SZ: 002275), which ended the year with a 41% increase. But the life science companies that listed on the ChiNext did even better -- often providing a 100% return or better. All of this is in sharp contrast to the experience of life science companies that chose to list on US exchanges. Complete Story » seekingalpha.com |